Prudential Financial Inc. decreased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 74.7% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 88,670 shares of the company’s stock after selling 261,600 shares during the period. Prudential Financial Inc.’s holdings in Amphastar Pharmaceuticals were worth $1,286,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in AMPH. Dimensional Fund Advisors LP raised its position in Amphastar Pharmaceuticals by 68.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 800,900 shares of the company’s stock valued at $14,753,000 after buying an additional 324,043 shares during the period. Sei Investments Co. raised its position in Amphastar Pharmaceuticals by 20,071.0% in the first quarter. Sei Investments Co. now owns 103,074 shares of the company’s stock valued at $1,495,000 after buying an additional 102,563 shares during the period. Nordea Investment Management AB purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at $1,486,000. State Street Corp raised its position in Amphastar Pharmaceuticals by 6.2% in the fourth quarter. State Street Corp now owns 955,991 shares of the company’s stock valued at $17,610,000 after buying an additional 55,688 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Amphastar Pharmaceuticals by 11.4% in the first quarter. Bank of New York Mellon Corp now owns 519,802 shares of the company’s stock valued at $7,536,000 after buying an additional 53,214 shares during the period. Institutional investors and hedge funds own 45.32% of the company’s stock.
Shares of Amphastar Pharmaceuticals, Inc. (AMPH) opened at 17.74 on Thursday. The stock has a market cap of $811.37 million, a price-to-earnings ratio of 93.37 and a beta of 1.68. Amphastar Pharmaceuticals, Inc. has a one year low of $12.05 and a one year high of $21.75. The company has a 50-day moving average of $17.37 and a 200 day moving average of $15.97.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Monday, May 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by $0.03. Amphastar Pharmaceuticals had a net margin of 3.54% and a return on equity of 2.69%. The business had revenue of $56.67 million during the quarter, compared to analyst estimates of $63.74 million. During the same period last year, the business posted $0.12 EPS. Amphastar Pharmaceuticals’s revenue was down 4.5% compared to the same quarter last year. On average, equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post $0.40 earnings per share for the current fiscal year.
WARNING: This piece was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://stocknewstimes.com/2017/07/20/prudential-financial-inc-decreases-position-in-amphastar-pharmaceuticals-inc-nasdaqamph.html.
Several research firms have recently weighed in on AMPH. TheStreet raised shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, June 26th. Jefferies Group LLC set a $21.00 target price on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, April 20th. Finally, Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Amphastar Pharmaceuticals has an average rating of “Buy” and an average target price of $20.14.
In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $17.07, for a total value of $170,700.00. Following the completion of the sale, the director now owns 28,844 shares of the company’s stock, valued at $492,367.08. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Michael A. Zasloff sold 15,000 shares of the firm’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $17.01, for a total value of $255,150.00. Following the completion of the sale, the director now directly owns 47,411 shares of the company’s stock, valued at approximately $806,461.11. The disclosure for this sale can be found here. In the last three months, insiders sold 43,982 shares of company stock valued at $735,850. 11.10% of the stock is owned by corporate insiders.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
